Molbio Diagnostics Seeks ₹940 Crore in IPO to Boost Growth

Molbio Diagnostics, a key player in the molecular diagnostics industry, has announced plans to raise ₹940 crore through its upcoming initial public offering (IPO). The funds will be divided between a fresh issuance of shares worth ₹200 crore aimed at capital expenditures and a ₹740 crore offer for sale to reduce promoter stake.

Expanding Global Reach and Reducing Promoter Stake

The IPO will see the promoter group's stake decrease from 46.6% to 43%. Molbio operates six manufacturing facilities across India and serves a diverse clientele in over 90 countries. These include government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Despite its wide reach, more than half of its revenue is concentrated among its top clients, indicating a potential risk factor for investors.

Financial Performance Driven by Tuberculosis Test Kits

Founded in 2000, Molbio has established itself in the research, development, and manufacturing of diagnostic solutions for a range of diseases. Its flagship product, the 'Truenat' platform, is a portable diagnostic system designed for use in resource-limited settings, delivering accurate test results in under an hour. The company offers molecular testing for over 30 diseases through 43 diagnostic assays.

Revenue from operations increased by 31.5% annually to ₹1,445.7 crore, with net profit rising by 40.2% to ₹164.1 crore between FY24 and FY26. The operating profit, or Ebitda, grew by 33.2% to ₹328.2 crore, with the Ebitda margin improving slightly to 22.6% in FY26 from 22% in FY24.

Molbio's financial growth is heavily reliant on its tuberculosis diagnostic test kits, which account for 70% of its test kit sales. This high dependency on a single product line could pose a risk if demand shifts or new competitors enter the market.

Valuation and Market Comparison

The IPO's pricing demands a price-earnings (P/E) multiple of up to 57, a figure that places Molbio in a competitive range with other healthcare diagnostics and medical device companies in India. Comparable firms such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre have P/E multiples ranging from 54 to 81.

While Molbio does not have a directly comparable listed peer in India, its focus on innovative diagnostic solutions and robust sales growth make it an attractive option for investors with a high-risk appetite. The company's strategic focus on expanding its global presence and diversifying its product offerings could provide substantial long-term growth opportunities.